Skip to main content
SpringerLink
Log in

Tumor Rejection Antigens and Immune Surveillance

  • Conference paper
Modern Trends in Human Leukemia IX

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 35))

  • 59 Accesses

Abstract

The existence of specific tumor rejection antigens was first demonstrated with chemically induced mouse sarcomas: each tumor was found to express a different antigen [1]. Similar findings were made with ultraviolet-induced tumors [2]. Later, the generality of the existence of tumor rejection antigens was questioned when spontaneous mouse tumors were found to be completely incapable of eliciting an immune rejection response [3]. However, further experiments demonstrated that even these tumors express weak transplantation antigens that are potential targets for immune rejection by the syngeneic host [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. INCI 18:769

    CAS  Google Scholar 

  2. Kripke MI (1981) Immunologic mechanism in UV radiation carcinogenesis. Adv Cancer Res 34:69

    Article  PubMed  CAS  Google Scholar 

  3. Hewitt HB, Blake ER, Walder AS (1976) A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 33:241

    Article  PubMed  CAS  Google Scholar 

  4. Van Pel A, Vessière F, Boon T (1983) Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med 157:1992

    Article  PubMed  Google Scholar 

  5. Boon T, Kellerman O (1977) Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant terato-carcinoma cell line. Proc Natl Acad Sci USA 74:272

    Article  PubMed  CAS  Google Scholar 

  6. Frost P, Kerbel R, Bauer E, Tartamella-Biondo R, Cefalu W (1983) Mutagen treatments as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res 43:125

    PubMed  CAS  Google Scholar 

  7. Boon T, van Pel A (1978) Teratocar-cinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci USA 75:1519

    Article  PubMed  CAS  Google Scholar 

  8. Boon T, van Snick J, van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. T lymphocyte-mediated cytolysis. J Exp Med 152:1184

    Article  PubMed  CAS  Google Scholar 

  9. Maryanski JL, van Snick J, Cerottini JC, Boon T (1982) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol 12:401

    Article  PubMed  CAS  Google Scholar 

  10. Maryanski JL, Boon T (1982) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Analysis of variants-specific antigens by selection of antigen-loss variants with cytolytic T-cell clones. Eur J Immunol 12:406

    Article  PubMed  CAS  Google Scholar 

  11. Maryanski J, Marchand M, Uyttenhove C, Boon T (1983) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Occasional escape from host rejection due to antigen-loss secondary variants. Int J Cancer 31:119

    Article  PubMed  CAS  Google Scholar 

  12. Van Pel A, de Plaen E, Boon T (1985) Selection of highly transfectable variant from mouse mastocytoma P815. Somatic Cell Mol Genet 11:467

    Article  Google Scholar 

  13. Wölfel T, van Pel A, de Plaen E, Lurquin C, Maryanski JL, Boon T (1987) Immunoenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. Detection of stable transfectants expressing a tun - antigen with a cytolytic T cell stimulation assay. Immunogenetics 26:178

    Article  PubMed  Google Scholar 

  14. De Plaen E, Lurquin C, van Pel A, Mariamé B, Szikora JP, Wölfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum−) variants of mouse tumor P815: cloning of the gene of tun− antigen P91A and identification of the tun− mutation. Proc Natl Acad Sci USA 85:2274

    Article  PubMed  Google Scholar 

  15. Szikora JP, van Pel A, Brichard V, André M, van Baren N, Henry P, de Plaen E, Boon T (1990) Structure of the gene of tun- transplantation antigen P35B: pre-sence of a point mutation in the antigenic allele. EMBO J 9:1041

    PubMed  CAS  Google Scholar 

  16. Sibille C, Chomez P, Wildmann C, van Pel A, de Plaen E, Maryanski JL, de Bergeyck V, Boon T (1990) Structure of the gene of tun- transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med 172:35

    Article  PubMed  CAS  Google Scholar 

  17. Lurquin C, van Pel A, Mariamé B, de Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T (1989) Structure of the gene of tun- transplantation antigen P91 A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293

    Article  PubMed  CAS  Google Scholar 

  18. Townsend ARM, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42:457

    Article  PubMed  CAS  Google Scholar 

  19. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959

    Article  PubMed  CAS  Google Scholar 

  20. Townsend ARM, Bastin J, Gould K, Brownlee GG (1986) Cytotoxic T lymphocytes recognize influenza haemagglu-tinin that lacks a signal sequence. Nature 324:575

    Article  PubMed  CAS  Google Scholar 

  21. Van den Eynde B, Lethé ?, van Pel A, de Plaen E, Boon T (1991) The gene coding for the main tumor rejection antigen of mouse tumor P815 is identical to the normal gene of the syngeneic DBA/2 mice. J Exp Med 173:1373

    Article  PubMed  Google Scholar 

  22. Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157:1040

    Article  PubMed  CAS  Google Scholar 

  23. Hültner L, Moeller J, Schmitt E, Jäger G, Reisbach G, Ring J, Dörmer P (1989) Thiol-sensitive mast cell lines derived from mouse bone marrow respond to a mast cell growth-enhancing activity different from both IL-3 and IL-4. J Immunol 142:3440

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brussels Branch, Ludwig Institute for Cancer Research, 74 avenue Hippocrate UCL 7459, B-1200, Brussels, Belgium

    T. Boon

  2. Cellular Genetics Unit, University of Louvain, 74 avenue Hippocrate UCL 7459, B-1200, Brussels, Belgium

    T. Boon

Authors
  1. B. Van den Eynde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Lethé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Van Pel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Boon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Knochenmark-Transplantation, Universitäts-Krankenhaus Eppendorf, Martinistr. 52, 2000, Hamburg 20, Germany

    Rolf Neth

  2. Shemyakin Institute of Bioorganic Chemistry, Miklukho-Maklaya Str. 16/10, 117871, Moscow, Russia

    Elena Frolova

  3. Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, 20205, USA

    Robert C. Gallo

  4. Chester Beatty Laboratories, Leukemia Research Fund Centre, Institute of Cancer Research, Fulham Road, London, SW 3 6JB, UK

    Melvyn F. Greaves

  5. Department of Bone Marrow Transplantation, N. N. Petrov Institute of Oncology, St. Petersburg, Russia

    Boris V. Afanasiev

  6. Klinik für Innere Medizin, Abteilung Hämatologie, Medizinische Fakultät der Humboldt-Universität Berlin, Schumannstr. 20/21, 1040, Berlin, Germany

    Elena Elstner

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Van den Eynde, B., Lethé, B., Van Pel, A., Boon, T. (1992). Tumor Rejection Antigens and Immune Surveillance. In: Neth, R., Frolova, E., Gallo, R.C., Greaves, M.F., Afanasiev, B.V., Elstner, E. (eds) Modern Trends in Human Leukemia IX. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 35. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76829-3_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76829-3_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-54360-2

  • Online ISBN: 978-3-642-76829-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation